Urgent Health Alert: Massive Recall of 600,000 Blood Pressure Medication Bottles Due to Contamination Risks Poses Serious Safety Concerns for Patients, Prompting Immediate Action From Health Authorities, Pharmacies, and Consumers to Prevent Potential Health Complications and Ensure Safe Treatment for Those Managing Hypertension, Highlighting Critical Oversight in Production.

More than 600,000 bottles of the blood pressure medication ramipril have been recalled across the United States due to concerns about potential contamination. The recall was issued by the FDA after discovering that ingredients were sourced from an unapproved and uninspected manufacturing facility in India.

Ramipril is a commonly prescribed ACE inhibitor used to treat high blood pressure and reduce the risk of heart attack, stroke, and kidney damage. Each year, more than 2.4 million Americans rely on the medication, making the recall significant for patients and healthcare providers nationwide.

The affected products were manufactured by Lupin Pharmaceuticals and include ramipril capsules in 2.5 mg, 5 mg, and 10 mg strengths. Bottles containing 90, 100, or 500 capsules with expiration dates through July 2026 are included in the recall and were widely distributed through pharmacies and hospitals.